Jan 23, 2018
Pharma giant Celgene finally confirms USD 9 billion Juno Therapeutics buyout Celgene has finally confirmed the week-long rumor of buying Juno Therapeutics for a deal worth around USD 9 billion boosting its Grip in CAR-T therapy domain. A major reason for this buyout is Juno’s lead CAR-T drug candidate JCAR017 that ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper